Merck & Co., Inc. $MRK Position Lifted by Oppenheimer & Co. Inc.

Key Points

• Oppenheimer increased its Merck stake by 12.3% in the third quarter to 207,619 shares valued at approximately $30.2 million. Institutional investors collectively own 76.07% of the company.
• Analyst sentiment remains favorable, with a consensus “Moderate Buy” rating and an average price target of $153.12; Barclays recently raised its target to $180.
• Merck shares opened at $140.36, down 3.4%, as investors weigh positive oncology results against risks including Keytruda’s 2028 patent expiration, insider selling and potential limits on China biotech partnerships.

Oppenheimer & Co. Inc. boosted its position in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 12.3% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 207,619 shares of the company's stock after purchasing an additional 22,722 shares during the quarter. Oppenheimer & Co. Inc.'s holdings in Merck & Co., Inc. were worth $30,169,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of MRK. Dimensional Fund Advisors LP boosted its position in shares of Merck & Co., Inc. by 23.8% during the first quarter. Dimensional Fund Advisors LP now owns 15,456,039 shares of the company's stock worth $1,858,938,000 after purchasing an additional 2,969,856 shares in the last quarter. Bank of America Corp DE grew its holdings in shares of Merck & Co., Inc. by 10.5% in the 1st quarter. Bank of America Corp DE now owns 30,774,221 shares of the company's stock valued at $3,701,831,000 after buying an additional 2,919,780 shares during the period. Assenagon Asset Management S.A. grew its holdings in shares of Merck & Co., Inc. by 263.7% in the 2nd quarter. Assenagon Asset Management S.A. now owns 2,702,992 shares of the company's stock valued at $347,334,000 after buying an additional 1,959,778 shares during the period. Wellington Management Group LLP increased its position in shares of Merck & Co., Inc. by 2.3% in the 2nd quarter. Wellington Management Group LLP now owns 86,249,283 shares of the company's stock valued at $11,083,033,000 after buying an additional 1,934,312 shares in the last quarter. Finally, SEB Asset Management AB bought a new stake in shares of Merck & Co., Inc. in the 1st quarter valued at $197,550,000. Institutional investors own 76.07% of the company's stock.

Analyst Upgrades and Downgrades

MRK has been the topic of several recent analyst reports. Daiwa Securities Group upgraded Merck & Co., Inc. from a "neutral" rating to an "outperform" rating and set a $143.00 target price on the stock in a report on Wednesday, August 12th. Argus boosted their target price on Merck & Co., Inc. from $145.00 to $170.00 and gave the company a "buy" rating in a research note on Tuesday, August 25th. Wall Street Zen downgraded Merck & Co., Inc. from a "buy" rating to a "hold" rating in a report on Saturday, October 3rd. Sanford C. Bernstein raised their price target on Merck & Co., Inc. from $100.00 to $105.00 and gave the stock a "market perform" rating in a research report on Tuesday, August 4th. Finally, Barclays raised their price target on Merck & Co., Inc. from $150.00 to $180.00 and gave the stock an "overweight" rating in a research report on Monday. Seventeen analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $153.12.

Key Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck and partner Daiichi Sankyo reported positive Phase 3 results for sacituzumab tirumotecan (Sac-TMT) in certain patients with advanced or recurrent endometrial cancer. The treatment reduced the risk of death by 32% and the risk of disease progression or death by 41% versus chemotherapy; median overall survival was 19 months compared with 12.1 months. An FDA decision is expected by June 2027. Sac-TMT Phase 3 results
• Positive Sentiment: KEYTRUDA monotherapy reduced the risk of disease progression or death by 43% in a specified group of patients with mismatch repair-deficient endometrial cancer, reinforcing the drug’s oncology franchise and potential for additional indications. KEYTRUDA endometrial cancer results
• Positive Sentiment: Barclays raised its MRK price target to $180 from $150 and maintained an overweight rating. Another valuation update lifted fair value to $159.76 from $155.68, citing Merck’s oncology pipeline and cancer-vaccine partnership. Barclays price-target increase
• Neutral Sentiment: Merck and Moderna’s personalized melanoma vaccine reduced recurrence or death by 42% when added to KEYTRUDA in a Phase 3 trial. However, the result was below some elevated investor expectations, and overall-survival data remain immature. Merck’s October 29 earnings call may provide details on regulatory filings, launch economics and the vaccine’s role in offsetting future Keytruda losses.
• Negative Sentiment: Investors remain focused on Keytruda’s compound-patent expiration in December 2028. Upcoming results must show that newer products—including Winrevair, Keytruda QLEX and other pipeline assets—can support management’s “shallow dip” outlook.
• Negative Sentiment: New U.S. Treasury restrictions on certain U.S. collaborations and investments involving Chinese biotech companies could limit Merck’s access to partnerships, research and potential cancer-drug candidates from China. China biotech restrictions and Merck

Merck & Co., Inc. Trading Down 3.4%

NYSE MRK opened at $140.36 on Tuesday. The stock has a market capitalization of $346.28 billion, a price-to-earnings ratio of 112.29, a PEG ratio of 6.74 and a beta of 0.21. The stock's 50 day moving average price is $146.69 and its two-hundred day moving average price is $125.84. The company has a debt-to-equity ratio of 1.22, a quick ratio of 1.10 and a current ratio of 1.32. Merck & Co., Inc. has a 52 week low of $82.01 and a 52 week high of $156.92.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.13. The company had revenue of $16.61 billion during the quarter, compared to analysts' expectations of $16.37 billion. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. The business's quarterly revenue was up 5.1% on a year-over-year basis. During the same period last year, the business earned $2.13 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, analysts anticipate that Merck & Co., Inc. will post 2.64 earnings per share for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, October 7th. Stockholders of record on Tuesday, September 15th were given a $0.85 dividend. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.4%. The ex-dividend date of this dividend was Tuesday, September 15th. Merck & Co., Inc.'s payout ratio is currently 272.00%.

Insider Buying and Selling at Merck & Co., Inc.

In related news, EVP Jennifer Zachary sold 80,315 shares of the stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $133.46, for a total transaction of $10,718,839.90. Following the completion of the transaction, the executive vice president owned 45,509 shares in the company, valued at approximately $6,073,631.14. This represents a 63.83% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP David Maraldo sold 18,706 shares of the firm's stock in a transaction on Wednesday, August 5th. The shares were sold at an average price of $128.72, for a total transaction of $2,407,836.32. Following the completion of the transaction, the executive vice president directly owned 18,212 shares of the company's stock, valued at approximately $2,344,248.64. This trade represents a 50.67% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 228,238 shares of company stock valued at $29,977,783 in the last three months. 0.17% of the stock is currently owned by insiders.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global healthcare company that develops, manufactures and markets prescription medicines, vaccines and animal-health products. Its pharmaceutical business focuses on oncology, infectious diseases, cardiology, immunology and other areas of significant medical need. The company serves patients, healthcare providers and institutions in markets worldwide.

Merck's principal products include Keytruda, an immunotherapy used to treat a range of cancers; Gardasil and Gardasil 9, vaccines that help protect against human papillomavirus; and Januvia and Janumet, medicines used to manage type 2 diabetes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.